Common cholesterol drug tested as potential lifeline for rare liver disease

NCT ID NCT04133792

Ongoing Disease control Sponsor: Annika Bergquist Source: ClinicalTrials.gov ↗

Summary

This large, late-stage study is testing whether a common cholesterol-lowering drug, simvastatin, can improve the long-term outlook for people with primary sclerosing cholangitis (PSC), a rare liver disease. About 570 adults with PSC will take either simvastatin or a placebo pill daily for five years. Researchers will see if the drug can delay or prevent serious outcomes like the need for a liver transplant, liver cancer, or death.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Akademiska sjukhuset

Uppsala, 751 85, Sweden
Danderyds sjukhus

Stockholm, 182 57, Sweden
Karlstads centralsjukhus

Karlstad, 652 30, Sweden
Karolinska University Hospital

Stockholm, 141 57, Sweden
Karolinska University Hospital Solna

Stockholm, 171 64, Sweden
Norrlands Universitetssjukhus

Umeå, Västerbotten County, 907 37, Sweden
Sahlgrenska Universitetssjukhuset

Gothenburg, Västra Götaland County, 413 45, Sweden
Sahlgrenska Universitetssjukhuset Östra

Gothenburg, 41685, Sweden
Skaraborgs sjukhus

Lidköping, Sweden
Skåne Universitetssjukhus

Malmo, Skåne County, 222 42, Sweden
Universitetssjukhuset i Linköping

Linköping, Östergötland County, 581 85, Sweden
Örebro Universitetssjukhus

Örebro, 701 85, Sweden

Conditions

Explore the condition pages connected to this study.

PRIMARY SCLEROSING CHOLANGITIS